GenSight Biologics S.A.
GSGTFOTCHealthcare● Active
$0.19
+$0.00(+0.00%)
Market Cap$30986300
P/E Ratio—
52W High$0.48
52W Low$0.1901
GenSight Biologics S.A. (GSGTF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GSGTF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00M | $1.50M | $1.27M | $2.58M | $5.28M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.00M | $1.50M | $1.27M | $2.58M | $5.28M |
| Gross Margin %(computed) | 100.04% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $6.44M | $12.37M | $19.36M | $18.94M | $22.55M |
| G&A Expenses | $2.54M | $3.58M | $6.50M | $8.01M | $5.68M |
| Total Operating Expenses | $11.06M | $17.31M | $30.96M | $30.42M | $33.40M |
| Operating Income | ($11.70M) | ($15.81M) | ($29.70M) | ($27.84M) | ($28.13M) |
| Operating Margin %(computed) | — | — | — | — | -533.09% |
| Interest Income | $0.00M | $0.00M | $0.00M | $2.65M | $0.00M |
| Interest Expense | $0.99M | $1.55M | $3.15M | $2.65M | $2.17M |
| Income Before Tax | ($12.04M) | ($13.98M) | ($27.92M) | ($27.62M) | ($28.61M) |
| Income Tax Expense | $0.00M | $0.02M | ($1.70M) | $0.01M | $0.00M |
| Net Income | ($12.03M) | ($14.00M) | ($26.22M) | ($27.62M) | ($28.62M) |
| Net Margin %(computed) | — | -933.40% | — | — | -542.40% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.08 | $-0.17 | $-0.54 | $-0.60 | $-0.63 |
| Wtd Avg Shares | 148.30M | 82.75M | 48.32M | 46.33M | 45.15M |
| EBITDA | ($11.24M) | ($11.37M) | ($20.89M) | ($26.77M) | ($27.20M) |
| EBITDA Margin %(computed) | — | -757.93% | — | — | -515.52% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · EUR · M
Explore more GenSight Biologics S.A. data
About GenSight Biologics S.A. (GSGTF) Income Statement
GenSight Biologics S.A. (GSGTF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GSGTF reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.04%), and net income of ($0.01B) — a net profit margin of -1203594.43%.
Frequently asked questions
GSGTF · 4 questionsGenSight Biologics S.A. (GSGTF) reported revenue of $0.00B for 2025, down 99.9% year-over-year.
GSGTF revenueGSGTF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09